NITISINONE
| Brand name | ORFADIN |
|---|---|
| Active ingredient | NITISINONE |
| Strength | 4MG/ML |
| Dosage form | SUSPENSION |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | April 2016 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9301932 | February 2033 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.